Saunders Nursing Drug Handbook 2019

3120 Pages·2018·10.81 MB·English

by  Robert J Kizior

Saunders Nursing Drug Handbook
2019

Robert J. Kizior, BS, RPh

Department of Pharmacy, Alexian Brothers Medical Center, Elk Grove Village,
Illinois

Keith J. Hodgson, RN, BSN, CCRN

Staff Nurse, Intensive Care Unit, Former Staff Nurse, Emergency Department,
St. Joseph’s Hospital, Tampa, Florida

Table of Contents

Cover image

Title page

Copyright

IFC

Newly Approved Medications

Author Biographies

Reviewers

Consultants

Acknowledgments

Dedication

Preface

Drug Classification Contents

Allergic Rhinitis Preparations

Beta-Adrenergic Blockers

Calcium Channel Blockers

Diuretics

H2 Antagonists

Immunosuppressive Agents

Laxatives

Multiple Sclerosis

Obesity Management

Parkinson's Disease Treatment

Sedative-Hypnotics

Vitamins

A

B

C

D

E

F

G

H

I

K

L

M

N

O

P

Q

R

S

T

U

V

W

Z

Appendix A

Appendix B

Appendix C

Appendix D

Appendix E

Appendix F

Appendix G

Appendix H

Appendix I

Appendix J

Appendix K

Appendix L

Appendix M

evolve

Index

Commonly Used Abbreviations

Copyright

3251 Riverport Lane
St. Louis, Missouri 63043

SAUNDERS NURSING DRUG HANDBOOK 2019

ISBN: 978-0-323-60885-5
ISSN: 1098-8661

Copyright © 2019, 2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010,
2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998, 1997,
1996, 1995, 1994, 1993 by Elsevier Inc. All rights reserved.

All rights reserved. No part of this publication may be reproduced or transmitted
in any form or by any means, electronic or mechanical, including photocopying,
recording, or any information storage and retrieval system, without permission in
writing from the publisher. Details on how to seek permission, further
information about the Publisher’s permissions policies and our arrangements
with organizations such as the Copyright Clearance Center and the Copyright
Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under
copyright by the Publisher (other than as may be noted herein).

Notices

Practitioners and researchers must always rely on their own experience and
knowledge in evaluating and using any information, methods, compounds, or
experiments described herein. Because of rapid advances in the medical
sciences, in particular, independent verification of diagnoses and drug dosages

should be made. To the fullest extent of the law, no responsibility is assumed
by Elsevier, authors, editors, or contributors for any injury and/or damage to
persons or property as a matter of products liability, negligence, or otherwise,
or from any use or operation of any methods, products, instructions, or ideas
contained in the material herein.

ISBN: 978-0-323-60885-5

Executive Content Strategist: Sonya Seigafuse
Content Development Manager: Lisa Newton
Senior Content Development Specialist: Tina Kaemmerer, Charlene Ketchum
Publishing Services Manager: Julie Eddy
Project Manager: Mike Sheets
Design Direction: Ryan Cook

Printed in the United States of America

Last digit is the print number: 9 8 7 6 5 4 3 2 1

IFC

IV Compatibilities
The IV compatibility table provides data when 2 or more medications are given
in a Y-site of administration. The data in this table largely represent physical
incompatibilities (e.g., haze, precipitate, change in color). Therapeutic
incompatibilities have not been included, so when using the table, professional
judgement should be exercised.
C Physically compatible via Y-site administration.
I Physically incompatible.
N Information on compatibility not available or conflicting

Dextrose 5%
Sodium

Chloride

Acyclovir
Amikacin
Amiodarone
Anidulafungin
Argatroban
Azithromycin

Acyclovir
C
C
—
C
N
C
N

Amikacin
C
C
C
—
C
C
N

Amiodarone
C
C
N
C
—
N
I

Anidulafungin
C
C
C
C
N
—
N

Argatroban
C
C
N
N
I
N
—

Azithromycin
C
C
N
I
N
N
N

Aztreonam
C
C
I
C
N
N
N

Bivalirudin
C
C
N
C
I
N
N

Bumetanide
C
C
N
N
N
N
N

Calcium Gluconate
C
C
N
C
C
N
N

Cefazolin
C
C
C
C
I
C
N

Cefepime
C
C
N
C
N
C
N

Ceftaroline Fosamil
C
C
C
C
C
N
N

Ceftriaxone
C
C
C
C
C
C
N

Ciprofloxacin
C
C
N
C
C
C
N

Clevidipine
C
C
N
N
N
N
N

Clindamycin
C
C
C
C
C
C
N

Daptomycin
I
C
N
C
N
N
N

Dexamethasone
C
C
C
C
N
C
N

Dexmedetomidine
C
C
N
C
C
N
N

Diltiazem
C
C
I
C
N
N
C

Diphenhydramine
C
C
C
C
N
N
C

Dobutamine
C
C
I
N
C
C
C

Dopamine
C
C
I
N
C
C
C

Enalapril
C
C
N
C
N
N
N

Epinephrine
C
C
N
C
C
C
N

Eptifibatide
C
C
N
N
C
N
C

Esmolol
C
C
N
C
C
N
N

Famotidine
C
C
C
N
C
C
N

Fluconazole
C
C
C
C
C
C
N

Furosemide
C
C
N
C
C
C
C

Gentamicin
C
C
C
N
C
C
N

Granisetron
C
C
C
C
N
N
N

Heparin
C
C
C
I
I
C
N

Hydrocortisone
C
C
C
C
N
C
C

Hydromorphone
C
C
C
C
N
N
N

Imipenem
C
C
C
N
I
C
N

Insulin
N
C
N
N
C
N
N

Labetalol
C
C
N
C
C
N
N

Levofloxacin
C
C
I
C
N
C
N

Linezolid
C
C
C
C
N
C
N

Lorazepam
N
C
C
C
C
N
N

Magnesium
C
C
C
C
I
N
N

Mannitol
—
—
N
C
N
N
N

Meropenem
N
C
I
N
N
C
N

Methylprednisolone
C
C
C
N
C
C
N

Metoclopramide
C
C
C
N
N
N
N

Metronidazole
—
—
C
N
N
C
N

Midazolam
C
C
N
C
C
C
C

Morphine
C
C
C
C
C
C
C

Nicardipine
C
C
N
C
N
N
N

Nitroglycerin
C
C
N
N
C
N
C

Nitroprusside
C
C
N
N
I
N
C

Norepinephrine
C
C
N
C
C
C
C

Octreotide
C
C
N
N
N
N
N

Ondansetron
C
C
I
C
N
N
N

Pantoprazole
C
C
N
I
I
C
N

Phenylephrine
C
C
N
N
C
C
C

Piperacillin/Tazobactam
C
C
I
N
I
C
N

Potassium Chloride
C
C
C
C
C
C
N

Propofol
C
C
C
I
N
N
N

Sodium Bicarbonate
C
C
C
C
I
I
N

Tigecycline
C
C
N
C
N
N
N

Tobramycin
C
C
C
N
C
C
N

Vancomycin
C
C
C
C
C
C
N

Vasopressin
—
C
N
N
C
N
C

Newly Approved Medications

Abaloparatide (Tymlos)
Treatment of postmenopausal women with osteoporosis at high risk for fracture

Avelumab (Bavencio)
A monoclonal antibody for metastatic Merkel cell carcinoma

Betarixaban (Bevyxxa)
Factor Xa inhibitor for prophylaxis of venous thromboembolism

∗Bezlotoxumab (Zinplava)
A monoclonal antibody to reduce recurrence of C. difficile infection

Brigatinib (Alunbrig)
Treatment on NSCLC who have progressed or are intolerant to crizotinib

Brodalumab (Sililq)
An IL-17RA antagonist for moderate to severe plaque psoriasis

∗Cerliponase alfa (Brineura)
Slow loss of ambulation tripeptidyl peptidase 1 deficiency

Clevidipine (Cleviprex)
Management of hypertension when oral therapy not feasible

∗Deflazacort (Emflaza)
An oral corticosteroid for Duchenne muscular dystrophy

Delafloxacin (Baxdela)
A fluoroquinolone for treatment of skin and skin structure infections

∗Deutetrabenazine (Austedo)
A VMAT2 inhibitor for chorea associated with Huntington’s disease

∗Dupilumab (Dupixent)
An IL-4RA antagonist for moderate to severe eczema (atopic dermatitis)

Durvalumab (Imfinzi)
Treatment of locally advanced or metastatic urothelial carcinoma

∗Etelcalcetide (Parsabiv)
A calcium sensing receptor agonist for secondary hyperparathyroidism in

patients with chronic kidney disease on hemodialysis

Guselkumab (Tremfya)
Interleukin blocker for treatment of adulst with moderate to severe plaque

psoriasis

Ledipasvir/sofosbuvir (Harvoni)
Treatment of chronic hepatitis C genotypes 1,4,5,6

Midostaurin (Rydapt)
Kinase inhibitor for treatment of newly diagnosed acute myeloid leukemia

Naldemedine (Symproic)
An opioid antagonist for opioid-induced constipation

Naloxegol (Movantik)
Treatment of opioid induced constipation for chronic pain

Neratinib (Nerlynx)
Kinase inhibitor for extended adjuvant treatment of breast cancer

Niraparib (Zejula)
A PARP inhibitor for recurrent epithelial ovarian, fallopian tube, or primary

peritoneal cancer

Ocrelizumab (Ocrevus)
A monoclonal antibody for relapsing or primary progressive forms of multiple

sclerosis

Olaratumab (Lartruvo)
A PDGFR-alpha blocking antibody for soft tissue sarcoma

Plecanatide (Trulance)
A guanylate cyclase-C agonist for chronic idiopathic constipation

Ponatinib (Iclusig)
Kinase inhibitor for treatment of acute lymphoblastic and chronic myeloid

leukemia

Ribociclib (Kisqali)
A kinase inhibitor for postmenopausal women with advanced breast cancer

Rucaparib (Rubraca)
An oral PARP inhibitor for certain types of advanced ovarian cancer

Safinamide (Xadago)
An MAO-B inhibitor for Parkinson’s patients experiencing “off” episodes

Sarilumab (Kevzara)
Treatment of moderate to severe active rheumatoid arthritis

Sofosbuvir/velpatasvir/voxilaprevir

(Vosevi)

Fixed combination for treatment of chronic HCV genotypes 1, 2, 3, 4, 5 or 6

∗Telotristat (Xermelo)
An oral tryptophan hydroxylase inhibitor for carcinoid syndrome diarrhea

Valbemazine (Ingrezza)
A selective VMATZ inhibitor for the treatment of tardive dyskinesia

Ziv-Aflibercept (Zaltrap)
Treatment of colorectal cancer, metastatic

∗ Featured on Evolve only

Author Biographies

Robert (Bob) J. Kizior, BS, RPh

Bob graduated from the University of Illinois School of Pharmacy and is
licensed to practice in the state of Illinois. He has worked as a hospital
pharmacist for more than 40 years at Alexian Brothers Medical Center in Elk
Grove Village, Illinois—a suburb of Chicago. Bob is the Pharmacy Surgery
Coordinator for the Department of Pharmacy, where he participates in
educational programs for pharmacists, nurses, physicians, and patients. He plays
a major role in coordinating pharmacy services in the OR satellite. Bob is a
former adjunct faculty member at William Rainey Harper Community College in
Palatine, Illinois.

An avid sports fan, Bob also has eclectic tastes in music that range from
classical, big band, rock ‘n’ roll, and jazz to country and western. Bob spends
much of his free time reviewing the professional literature to stay current on new
drug information.

Keith J. Hodgson, RN, BSN, CCRN

Keith was born into a loving family in Chicago, Illinois. His mother, Barbara B.
Hodgson, was an author and publisher of several medication products, and her
work has been a part of his life since he was a child. By the time he was 4 years
old, Keith was already helping his mother with the drug cards by stacking the
draft pages that were piled up throughout their home.

Because of his mother’s influence, Keith contemplated becoming a nurse in
college, but his mind was fully made up after he shadowed his sister in the
Emergency Department. Keith received his Associates Degree in Nursing from
Hillsborough Community College and his Bachelor of Science in Nursing from
the University of South Florida in Tampa, Florida. Keith started his career in the
Emergency Department and now works in the Trauma/Neurological/Surgical
Intensive Care Unit at St. Joseph’s Hospital in Tampa, Florida.